個案資料
了解個案內容與學習目標，選擇授課教師及使用課程。
Market Dynamics and Moral Dilemmas: Novo Nordisk's Weight-Loss Drugs
內容大綱
Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of safe, effective weight loss. As demand in the U.S. reached a fever pitch, Novo faced opportunities and challenges. The case covers the markets in which Novo could expand, the manufacturing shortfalls it faced, the competition that was expected to arise, and the moral issues that came with selling a product that affected so many people worldwide.
涵蓋主題
- Personal purpose and values
- Corporate social responsibility
- Global strategy
- Supply chain management
- Business ethics
- Supply and demand
- Compensation and benefits
- Patents
- Philanthropy
- Healthcare and treatment
- Business growth
- Product positioning
- Decision making
- Strategy
- Mission statements
- Growth strategy